Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
Phase III, Multicentre, Open Study to Assess the Efficacy and Safety Profiles of the Co-administration of Lanreotide Autogel 120 mg (Administered Via Deep Subcutaneous Injections Every 28 Days) and Pegvisomant 40 to 120 mg Per Week (Administered Via Subcutaneous Route Once or Twice a Week) in Acromegalic Patients Failing to Respond to Lanreotide Autogel 120 mg Alone
Sponsor: Ipsen
Listed as NCT00383708, this PHASE3 trial focuses on Acromegaly and remains completed. Sponsored by Ipsen, it has been updated 12 times since 2006, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Mar 2022 — Sep 2022 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jan 2022 — Mar 2022 [monthly]
Completed PHASE3
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE3
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Aug 2018 — Feb 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Oct 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ipsen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarhus, Denmark , Alicante, Spain , Berlin, Germany , Créteil, France , Frankfurt, Germany , Gothenburg, Sweden , Hradec Králové, Czechia , Le Kremlin-Bicêtre, France , Leiden, Netherlands , Lille, France and 14 more locations